Pertuzumab, Trastuzumab, and Docetaxel in HER2-Positive Metastatic Breast Cancer

BACKGROUND: In patients with metastatic breast cancer that is positive for human epidermal growth factor receptor 2 (HER2), progression-free survival was significantly improved after first-line therapy with pertuzumab, trastuzumab, and docetaxel, as compared with placebo, trastuzumab, and docetaxel....

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:N Engl J Med
Main Authors: Swain, Sandra M., Baselga, José, Kim, Sung-Bae, Ro, Jungsil, Semiglazov, Vladimir, Campone, Mario, Ciruelos, Eva, Ferrero, Jean-Marc, Schneeweiss, Andreas, Heeson, Sarah, Clark, Emma, Ross, Graham, Benyunes, Mark C., Cortés, Javier
Formato: Artigo
Idioma:Inglês
Publicado em: 2015
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5584549/
https://ncbi.nlm.nih.gov/pubmed/25693012
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1056/NEJMoa1413513
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados